BRAF V600E

P2, N=15, Completed, Scripps Health | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Apr 2026 | Trial primary completion date: Dec 2026 --> Apr 2026

When tested against TP53-mutated colorectal cancer (CRC) patient-derived organoids (PDOs) grown from peritoneal and liver metastases, 14 exhibited outstanding anticancer efficacy, surpassing previously reported branched alkane counterpart 3, as well as clinical candidates AZD1775 (1) and ZN-c3 (2). Against primary CRC PDOs (TP53-WT, BRAF-V600E, KRAS-WT), 14 profoundly elevated DNA damage and replication stress compared to 1, while amplifying cellular apoptosis, confirming a broadly similar but superior mode of action. Owing to its highly selective and exemplary anticancer efficacy, 14 represents a valuable tool compound for drug testing investigations against primary and metastatic CRCs, especially in the context of PDOs.

Subsequent next-generation sequencing confirmed a BRAF V600E mutation in the latter. This case highlights the dual diagnostic utility of VE1 IHC in differentiating benign ciliated epithelium from malignant cells.

Vemurafenib increases miR-31-5p in keratinocyte-derived exosomes, which suppresses ALKBH1 and elevates RNA m6A in melanoma cells, thereby promoting proliferation and reducing vemurafenib sensitivity. Targeting the miR-31-5p/ALKBH1 axis and m6A modification may offer a potential therapeutic strategy to enhance vemurafenib sensitivity in BRAFV600E melanoma cells.

This case suggests that the combination of cladribine and low-dose rituximab may be an effective therapeutic strategy for classical HCL with TP53 abnormality, enabling deep molecular response and reversal of associated bone marrow fibrosis. Further prospective studies are warranted to validate these findings.

In each molecular category, secondary alterations can occur; most notably TERT promoter and TP53 mutations occur with increasing frequency in high-grade differentiated, poorly differentiated, and anaplastic thyroid carcinomas. This article will review the diagnostic, prognostic, and therapeutic significance of molecular alterations across the spectrum of follicular cell derived thyroid tumors and discuss strategies for investigating unusual molecular alterations encountered in clinical practice.

The median AD was significantly higher in the BRAFp.V600E mutated DTC lesions than in the RAS mutated DTC lesions. BRAFp.V600E mutated DTC lesions with a partial and complete response received significantly higher doses than other lesions.

These tumors are relatively aggressive and often associated with multiple mutations, including those associated with their aggressive clinical behavior. A review of similar reported tumors in the literature is discussed herewith.

HGDTC presents with more aggressive characteristics and a worse prognosis. Accurate diagnosis, molecular profiling, and long-term monitoring are essential for optimal management.

The story has come full circle, and the recent proposal to incorporate FVPTC into follicular adenoma is in keeping with Lindsay's original concept. By the current understanding, these nuclei are classified better by molecular associations.

The Idylla BRAF assay delivers ultrarapid results that are both reliable and accurate with high success rates, particularly on ScfDNA samples. ScfDNA samples also have the fastest TAT because no histologic processing or pre-extraction are required for testing.

P1, N=267, Recruiting, Pfizer | Trial completion date: May 2030 --> Aug 2030 | Trial primary completion date: Nov 2028 --> Feb 2029